Author

Brita Bjerregaard Jensen

Observed names: B. B. Jensen, B. Bjerregaard jensen, B.B. Jensen, B.K. Bjerregaard, Brita B. Jensen, Brita Bjerregaard

Observed institutions: Aarhus University, Roskilde Sygehus, Aalborg University Hospital, Odense University Hospital, Herlev Hospital, Aarhus University Hospital, Copenhagen University Hospital, Rigshospitalet, Vejle Sygehus, Hospital South West Jutland, Queen Ingrid's Hospital

OpenAlex ID: A5083259679

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

2017 · Miguel Martin, Frankie A Holmes, et al. · The Lancet Oncology · 599

Cervical lymph node metastases from unknown primary tumours

2000 · Cai Grau, Lars Vendelbo Johansen, et al. · Radiotherapy and Oncology · 346

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

2013 · S. Kubicka, R. Greil, et al. · Annals of Oncology · 108

Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer

2013 · M.K. Boisen, J.S. Johansen, et al. · Annals of Oncology · 88

Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer

2008 · Bent Kristensen, Bent Ejlertsen, et al. · Acta Oncologica · 70

Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer

2007 · Bent Ejlertsen, Henning T. Mouridsen, et al. · European Journal of Cancer · 63

Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab

2014 · Mogens K. Boisen, Christian Dehlendorff, et al. · PLoS ONE · 44

A phase II study of a 3-day schedule with topotecan and cisplatin every three weeks in patients with previously in treated small cell lung cancer and extensive disease: Final results

2004 · U. Lassen, M. Sørensen, et al. · Journal of Clinical Oncology · 3

Is metronomic chemotherapy less toxic than conventional chemotherapy in the randomized phase 2 XeNa trial combining navelbine oral and Xeloda for HER2 negative breast cancer patients

2015 · Anne Sofie Brems-Eskildsen, Soeren Linnet, et al. · Repositorio Institucional E-DocUR (Universidad Del Rosario) · 1

Primary tumor location and expression of mir-664 as a combined biomarker for bevacizumab effectiveness in metastatic colorectal cancer.

2013 · Mogens Karsboel Boisen, Christian Dehlendorff, et al. · Journal of Clinical Oncology · 1

Metastatic or Locally Advanced Colorectal Cancer Treated with 5-Fluorouracil and Low Dose Leucovorin

1994 · Lisbeth J. Andersen, Niels H. Brunsgaard, et al. · Acta Oncologica · 1

RWD53 A Real-World Analysis of Treatment Patterns for First-Line Immunotherapies Among Danish Patients with Non-Small Cell Lung Cancer (NSCLC) and PD-L1 Expression ≥50%

2023 · D.M. Clugston, C. Beck, et al. · Value in Health

P-61 Polychemotherapy including topotecan combined with twice-daily accelerated radiotherapy in small cell lung cancer (SCLC). Preliminary data from a phase II trial

2003 · Morten Sorensen, Ulrik Lassen, et al. · Lung Cancer

Cervical lymph node metastases from unknown primary tumours: results from a Danish national survey

2000 · C. Grau, L. Vendelbo johansen, et al. · Clinical Otolaryngology

Management of cervical lymph node metastases from unknown primary tumours — results from a Danish national survey

1999 · C. Grau, L.V. Johansen, et al. · European Journal of Cancer

Works count: 15

Citation count: 1,324

H-index: 7

I10-index: 7